SciELO - Scientific Electronic Library Online

 
vol.99 número2Cirurgia valvar mitral e da comunicação interatrial: abordagem minimamente invasiva ou por esternotomiaImplante por cateter de bioprótese valvar para tratamento da estenose aórtica: experiência de três anos índice de autoresíndice de assuntospesquisa de artigos
Home Pagelista alfabética de periódicos  

Arquivos Brasileiros de Cardiologia

versão impressa ISSN 0066-782X

Resumo

MARTINS, Gerez Fernandes et al. Trimetazidine and inflammatory response in coronary artery bypass grafting. Arq. Bras. Cardiol. [online]. 2012, vol.99, n.2, pp. 688-696.  Epub 13-Jul-2012. ISSN 0066-782X.  http://dx.doi.org/10.1590/S0066-782X2012005000066.

BACKGROUND: Organic inflammatory response is a pathophysiological mechanism present at every coronary artery bypass grafting with extracorporeal circulation (CABG-ECC), the release of inflammatory mediators being one of its defense mechanisms. OBJECTIVE: To assess, in a prospective double-blind randomized and placebo-controlled study, the effects of trimetazidine (Tmz) on the inflammatory response, by using the variation in interleukins 6 and 8, TNF-α, complements C3 and C5, and highly sensitive C-reactive protein (HS-CRP) levels in the pre- and post-operative periods. METHODS: This study assessed 30 patients undergoing CABG-ECC with intermittent hypothermic cardioplegia, and having, at most, mild ventricular dysfunction. The patients were divided into two groups (placebo and Tmz), stratified by echocardiography, and received drug/placebo at the dose of 60 mg/day. Measurements were taken as follows: in the pre-operative period with no drug; on the day of surgery, corresponding to 12 to 15 days on drug/placebo; five minutes after aortic unclamping; 12 and 24 hours after surgery, for interleukins and complements; and 48 hours after surgery, for HS-CRP. RESULTS: No significant difference between the levels of interleukin 8, TNF-α, C3 and C5, and HS-CRP was observed. However, the interleukin 6 levels were significantly lower in the group treated as compared with those in the control group at all time points assessed. CONCLUSION: Trimetazidine proved to be effective only for reducing interleukin 6 in patients undergoing CABG.

Palavras-chave : Trimetazidine [administration & dosage]; inflammation; myocardial revascularization; myocardial reperfusion.

        · resumo em Português     · texto em Português | Inglês     · pdf em Português | Inglês